Pro-apoptotic effects of pycnogenol on HT1080 human fibrosarcoma cells

• Published in: International journal of oncology Vol. 46; no. 4; pp. 1629 - 1636
• Main Authors: HARATI, KAMRAN, SLODNIK, PAWEL, CHROMIK, ANSGAR MICHAEL, BEHR, BJÖRN, GOERTZ, OLE, HIRSCH, TOBIAS, KAPALSCHINSKI, NICOLAI, KLEIN-HITPASS, LUDGER, KOLBENSCHLAG, JONAS, UHL, WALDEMAR, LEHNHARDT, MARCUS, DAIGELER, ADRIEN
• Format: Journal Article
• Language: English
• Published: Greece D.A. Spandidos 01.04.2015; Spandidos Publications; Spandidos Publications UK Ltd
• Subjects: Adult; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - pharmacokinetics; Apoptosis; Apoptosis - drug effects; cancer; Cancer therapies; Care and treatment; catechin; Catechin - pharmacology; Cell Line, Tumor; Cell Proliferation - drug effects; Chemotherapy; CTNNA1; Disease; Drug Synergism; epicatechin; Female; Fibrosarcoma; Fibrosarcoma - drug therapy; Fibrosarcoma - genetics; Fibrosarcoma - pathology; Flavonoids; Flavonoids - administration & dosage; Flavonoids - pharmacokinetics; fluorescence-activated cell sorting; FN1; gene expression; Gene Expression Regulation, Neoplastic - drug effects; Gene Expression Regulation, Neoplastic - genetics; Genes; Health aspects; Humans; ITGB1; JAK1; Kinases; LAMC1; Male; Metastasis; Molecular Sequence Data; necrosis; Phosphatase; pycnogenol; Quercetin - analogs & derivatives; Quercetin - pharmacology; Response rates; RHOA; Sarcoma; Signal Transduction - drug effects; soft tissue sarcoma; taxifolin; Young Adult; United States > US; Europe
• ISSN: 1019-6439; 1791-2423
• DOI: 10.3892/ijo.2015.2854

Complete surgical resection with clear margins remains the mainstay of therapy for localised fibrosarcomas. Nevertheless, metastatic fibrosarcomas still represent a therapeutic dilemma. Commonly used chemotherapeutic agents like doxorubicin have proven to be effective in <30% of all cases of disseminated fibrosarcoma. Especially elderly patients with cardiac subdisease are not suitable for systemic chemotherapy with doxorubicin. Therefore we tested the apoptotic effects of the well-tolerated pine bark extract pycnogenol and its constituents on human fibrosarcoma cells (HT1080). Ten healthy subjects (six females, four males, mean age 24.8±6 years) received a single dose of 300 mg pycnogenol orally. Blood plasma samples were obtained before and 6 h after intake of pycnogenol. HT1080 cells were treated with these plasma samples. Additionally, HT1080 were incubated separately with catechin, epicatechin and taxifolin that are known as the main constituents of pycnogenol. Vital, apoptotic and necrotic cells were quantified using flow cytometric analysis. Gene expression was analyzed by RNA microarray. The results showed that single application of taxifolin, catechin and epicatechin reduced cell viability of HT1080 cells only moderately. A single dose of 300 mg pycnogenol given to 10 healthy adults produced plasma samples that led to significant apoptotic cell death ex vivo whereas pycnogenol-negative serum displayed no apoptotic activity. Microarray analysis revealed remarkable expression changes induced by pycnogenol in a variety of genes, which are involved in different apoptotic pathways of cancer cells [Janus kinase 1 (JAK1), DUSP1, RHOA, laminin γ1 (LAMC1), fibronectin 1 (FN1), catenin α1 (CTNNA1), ITGB1]. In conclusion, metabolised pycnogenol induces apoptosis in human fibrosarcoma cells. Pycnogenol exhibits its pro-apoptotic activity as a mixture and is more effective than its main constituents catechin, epicatechin and taxifolin indicating that the metabolised components interact synergistically. These results provide experimental support for in vivo trials assessing the effect of the pine bark extract pycnogenol.